Loading…
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-178M | $-174M | $-157M | -96.8% | - | - |
| 2024 | $0M | $-122M | $-125M | $-101M | -90.9% | - | - |
| 2023 | $0M | $-93M | $-96M | $-96M | -75.9% | -100.0% | - |
| 2022 | $8M | $-97M | $-86M | $-101M | -40.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 8.09 | 0 | 0 | 0 |
| Operating Expense | 107.37 | 104.31 | 129.73 | 179.21 |
| Operating Income | -99.27 | -104.31 | -129.73 | -179.21 |
| EBITDA | -96.87 | -92.99 | -121.90 | -177.57 |
| EBIT | -99.27 | -95.58 | -124.36 | -179.21 |
| Pretax Income | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income Common Stockholders | -85.98 | -96.02 | -124.70 | -174.32 |
| Total Expenses | 107.37 | 104.31 | 129.73 | 179.21 |
| Interest Expense | 0 | 0.44 | 0.34 | 0 |
| Interest Income | 2.62 | 7.58 | 9.47 | 10.11 |
| Research And Development | 78.42 | 76.56 | 96.43 | 140.32 |
| Selling General And Administration | 28.95 | 27.75 | 33.30 | 38.88 |
| Normalized EBITDA | -107.92 | -93.06 | -117.15 | -171.52 |
| Normalized Income | -97.04 | -96.08 | -119.95 | -168.28 |
| Basic EPS | -10.10 | -4.83 | -3.06 | 0 |
| Diluted EPS | -10.10 | -4.83 | -3.06 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 11.06 | 0.06 | -4.75 | -6.05 |
| Total Unusual Items Excluding Goodwill | 11.06 | 0.06 | -4.75 | -6.05 |
| Net Income From Continuing Operation Net Minority Interest | -85.98 | -96.02 | -124.70 | -174.32 |
| Reconciled Depreciation | 2.41 | 2.58 | 2.46 | 1.64 |
| Net Interest Income | 2.62 | 7.14 | 9.13 | 10.11 |
| Net Income From Continuing And Discontinued Operation | -85.98 | -96.02 | -124.70 | -174.32 |
| Total Operating Income As Reported | -106.45 | -104.25 | -129.73 | -179.21 |
| Diluted Average Shares | 8.51 | 19.88 | 40.82 | 0 |
| Basic Average Shares | 8.51 | 19.88 | 40.82 | 0 |
| Diluted NI Availto Com Stockholders | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income Including Noncontrolling Interests | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income Continuous Operations | -85.98 | -96.02 | -124.70 | -174.32 |
| Other Income Expense | 10.68 | 1.16 | -4.10 | -5.23 |
| Other Non Operating Income Expenses | -0.38 | 1.09 | 0.65 | 0.82 |
| Special Income Charges | 11.06 | 0.06 | 0 | 0 |
| Restructuring And Mergern Acquisition | -11.06 | -0.06 | 0 | 0 |
| Gain On Sale Of Security | 0 | 0 | -4.75 | -6.05 |
| Net Non Operating Interest Income Expense | 2.62 | 7.14 | 9.13 | 10.11 |
| Total Other Finance Cost | -2.62 | 0 | 0 | 0 |
| Interest Expense Non Operating | 0 | 0.44 | 0.34 | 0 |
| Interest Income Non Operating | 2.62 | 7.58 | 9.47 | 10.11 |
| General And Administrative Expense | 28.95 | 27.75 | 33.30 | 38.88 |
| Other Gand A | 28.95 | 27.75 | 33.30 | 38.88 |
| Operating Revenue | 8.09 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Solid Biosciences Inc.this co. | SLDB | $694M | - | 3.09 | -96.8% | -2.97 |
| Castle Biosciences, Inc. | CSTL | $734M | - | 1.53 | -5.1% | -224.72 |
| Absci Corporation | ABSI | $732M | - | 3.77 | -60.8% | -5.15 |
| CBLL | CBLL | $729M | - | 4.65 | -34.4% | -10.30 |
| Allogene Therapeutics, Inc. | ALLO | $726M | - |
| 1.65 |
| -65.3% |
| -1.79 |
| Gyre Therapeutics, Inc. | GYRE | $713M | 367.50 | 6.33 | 3.5% | 46.81 |
| Enhabit, Inc. | EHAB | $704M | - | 1.31 | -0.8% | 13.72 |
| Ironwood Pharmaceuticals, Inc. | IRWD | $683M | 27.67 | -2.58 | -9.2% | 8.78 |
| Bioventus Inc. | BVS | $654M | 29.30 | 3.52 | 10.0% | 12.31 |
| Peer Median | - | 29.30 | 2.59 | -7.2% | 3.50 | |